Advances in ApoA- I mimic peptides against atherosclerosis

Author: Chun-Xia HE ¹ ; Hui-Jin LI ¹ ; Wei QIN ¹ ; Lu XING ¹ ; Xin ZHOU ¹ ; Dong ZHAO ¹ ; Peng-Quan LI ¹ ; Xi JIN ¹ ; Hui-Ling CAO ¹
Author Information

1. Institute of Basic and Translalional Medicine, Xi' An Medical University, Shaanxi Key Lab of Ischemic Cardiovascular Disease
Publication Type:Journal Article
Keywords: a-helix; ApoA- I mimic peptide; apolipoprotein A-I; atherosclerosis; high density lipoprotein; reverse cholesterol transport
From: Chinese Pharmacological Bulletin 2021;37(2):155-160
CountryChina
Language:Chinese
Abstract: Apolipoprotein A-I (ApoA-I), the main protein component of high density lipoprotein (HDL) , which plays a key role in the process of reverse cholesterol transport (RCT) , is considered as an important anti-atherosclerosis (As) drug target. ApoA- I mimic peptides developed based on its a-helix, and HDL mimic peptides that developed by recombinant ApoA- I have entered clinical trials, exhibiting favorable RCT promotion and anli-As activity. The paper reviewed the advances in the structure and function of ApoA- I , the molecular interaction mechanism between ApoA-1 and ABCA1 ( ATP-binding cassette transporter Al) , LCAT (lecithin cholesterol acyl transferase) and SR-B1 (scavenger receptor class B type 1) , and anti- As activity of ApoA- I mimic peptides, which would provide references for anli-As new drug development based on ApoA- I mimic peptides.